Multiple sclerosis - established and novel therapeutic approaches.

Area of Science:

• Neurology
• Immunology
• Neuroscience

Background:

• Multiple sclerosis (MS) is a primary cause of neurological disability in young adults.
• MS pathology involves inflammation, demyelination, and axonal damage in the central nervous system.
• Current treatments offer non-specific anti-inflammatory effects with limited efficacy.

Purpose of the Study:

• To review advances in understanding MS pathophysiology.
• To explore novel therapeutic strategies targeting specific immune mechanisms and neurodegeneration.
• To highlight the need for personalized treatment approaches in MS.

Main Methods:

• Review of current literature on MS pathophysiology and emerging treatments.
• Categorization of therapeutic approaches including monoclonal antibodies, oral immunomodulators, and neuroprotective agents.
• Discussion of experimental strategies for axonal protection and regeneration.

Main Results:

• Targeted therapies like monoclonal antibodies (e.g., alemtuzumab, natalizumab) offer specific immune modulation.
• Oral agents (e.g., fingolimod) can modulate lymphocyte recirculation.
• Experimental approaches show promise in protecting axons and promoting remyelination.

Conclusions:

• Understanding MS disease progression and developing surrogate markers are crucial for personalized medicine.
• Future MS treatment will likely combine anti-inflammatory strategies with neuroprotection and repair.
• Optimized treatment requires a deeper understanding of individual disease pathogenesis.